Every 10-Q that SCYNEXIS, Inc. (SCYX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SCYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCYX filings page.
Scynexis, Inc., a clinical-stage biotech focused on rare kidney disease and invasive fungal infections, reported a Q2 2026 net income of $7.4 million, versus a loss a year earlier, largely driven by a $14.2 million noncash gain from warrant liability revaluation. Operating performance remained negative, with Q2 license revenue from its GSK agreement at $0.2 million and an operating loss of $7.8 million.
For the first six months of 2026, Scynexis recorded a net loss of $13.9 million on $0.2 million in revenue, as it increased investment in its pipeline. Research and development expense rose to $16.2 million, including an $8.0 million in-process R&D charge tied to acquiring the SCY-770 AMPK activator program for Autosomal Dominant Polycystic Kidney Disease. SG&A expenses were $8.7 million.
Liquidity improved following a March 2026 private placement that generated $40.0 million gross and $36.9 million net proceeds. As of June 30 2026, cash, cash equivalents and investments totaled $71.1 million, with total assets of $75.0 million and stockholders’ equity of $66.9 million. Management states these resources are sufficient to fund ongoing operations for at least 12 months and believes they extend the runway into 2029. A one-for-eight reverse stock split and subsequent authorized share increase also helped regain and support Nasdaq listing compliance.
SCYNEXIS, Inc. reported a Q1 2026 net loss of $21.3 million, widening from $5.4 million a year earlier, mainly due to an $8.0 million in-process R&D charge for acquiring SCY-770 and higher operating costs. Research and development expense rose to $12.4 million, while selling, general and administrative expense increased to $4.6 million, including $0.8 million of financing-related costs. A warrant fair value loss of $5.2 million also weighed on results. Cash, cash equivalents and investments were $72.4 million as of March 31, 2026, supported by a March 2026 private placement with gross proceeds of $40.0 million. The company believes these resources fund operations for at least 12 months and is advancing SCY‑770 for autosomal dominant polycystic kidney disease and SCY‑247 for invasive fungal infections.
SCYNEXIS (SCYX) reported Q3 2025 results. License revenue was $334,000, down from $660,000 a year ago. Operating expenses fell to $8.7 million, led by lower R&D at $5.5 million and SG&A of $3.3 million. The company posted a net loss of $8.6 million, or $0.17 per share, including a $0.6 million loss from warrant fair value adjustments.
Cash, cash equivalents, and short-term investments totaled $37.9 million as of September 30, 2025. Convertible notes were repaid at maturity in March 2025, reducing current debt to zero. A $10.0 million license receivable is on the balance sheet tied to the GSK collaboration.
After quarter-end, SCYNEXIS and GSK signed a binding memorandum of understanding under which SCYNEXIS will wind down the MARIO study and receive one-time payments totaling $24.8 million. Other potential milestones and royalties under the GSK license remain unchanged. The company also disclosed a Nasdaq minimum bid price notice received on June 20, 2025, with a compliance period through December 17, 2025.
SCYNEXIS, Inc. reported that the FDA lifted the clinical hold on ibrexafungerp on April 24, 2025, and dosing in the Phase 3 MARIO study resumed in May 2025, prompting the company to bill a $10.0 million development milestone to GSK in Q2 2025. The company is disputing GSK’s April 28, 2025 notice that purported to terminate the MARIO study and deny further milestone payments, including a $30.0 million milestone tied to study resumption.
Financially, SCYNEXIS recognized $1.364 million in license revenue for the quarter and reported a net loss of $6.885 million for Q2 2025 ($12.276 million year-to-date). Cash and investments totaled $46.5 million at June 30, 2025 (down from $75.1 million at year-end), the March 2019 convertible notes were repaid $14.0 million in March 2025, and the accumulated deficit was $388.8 million. The company received a Nasdaq deficiency notice on June 20, 2025 for a closing bid below $1.00 and has until December 17, 2025 to regain compliance. Ongoing securities class and derivative lawsuits remain pending.